Jiangsu Nanfang Medical Co (SHSE:603880) Piotroski F-Score: 6 (As of Jul. 28, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603880 Jiangsu Nanfang Medical Co Ltd SHSE:603880
50 GF Score
Price ¥6.96
GF Value ¥4.71
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Jiangsu Nanfang Medical Co Piotroski F-Score?

Jiangsu Nanfang Medical Co SHSE:603880 +9.78% 50 Piotroski F-Score is 6 as of Jul. 28, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates SHSE:603880 with a GF Score™ of 50/100 and a GF Value™ of ¥4.71 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 801 Medical Devices & Instruments companies, Jiangsu Nanfang Medical Co ranks better than 81.27% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jiangsu Nanfang Medical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Jiangsu Nanfang Medical Co's Piotroski F-Score or its related term are showing as below:

SHSE:603880' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Jiangsu Nanfang Medical Co was 8. The lowest was 1. And the median was 4.

Jiangsu Nanfang Medical Co  (SHSE:603880) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Jiangsu Nanfang Medical Co Piotroski F-Score Related Terms


Jiangsu Nanfang Medical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Jiangsu Nanfang Medical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Nanfang Medical Co Piotroski F-Score Chart

Jiangsu Nanfang Medical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 3.00 4.00 3.00 5.00

Jiangsu Nanfang Medical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 5.00 5.00 6.00

SHSE:603880 vs ISRG, BDX, MDLN: Piotroski F-Score Comparison

For the Medical Instruments & Supplies subindustry, Jiangsu Nanfang Medical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Nanfang Medical Co Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jiangsu Nanfang Medical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Jiangsu Nanfang Medical Co's Piotroski F-Score falls into.


SHSE:603880
50GF Score
Jiangsu Nanfang Medical Co Ltd SHSE:603880
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -5.05 + -11.96 + -76.782 + -5.09 = ¥-98.9 Mil.
Cash Flow from Operations was 27.743 + -8.311 + 20.847 + 42.456 = ¥82.7 Mil.
Revenue was 135.154 + 141.23 + 153.206 + 155.09 = ¥584.7 Mil.
Gross Profit was 16.769 + 16.334 + -24.346 + 14.098 = ¥22.9 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1038.259 + 986.986 + 993.458 + 927.942 + 912.659) / 5 = ¥971.8608 Mil.
Total Assets at the begining of this year (Mar25) was ¥1,038.3 Mil.
Long-Term Debt & Capital Lease Obligation was ¥67.0 Mil.
Total Current Assets was ¥316.7 Mil.
Total Current Liabilities was ¥660.1 Mil.
Net Income was -0.719 + -14.34 + -177.356 + -7.918 = ¥-200.3 Mil.

Revenue was 162.69 + 153.192 + 147.553 + 170.922 = ¥634.4 Mil.
Gross Profit was 26.938 + 12.146 + -70.594 + 14.673 = ¥-16.8 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1259.908 + 1326.776 + 1248.994 + 1056.553 + 1038.259) / 5 = ¥1186.098 Mil.
Total Assets at the begining of last year (Mar24) was ¥1,259.9 Mil.
Long-Term Debt & Capital Lease Obligation was ¥17.1 Mil.
Total Current Assets was ¥392.4 Mil.
Total Current Liabilities was ¥733.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jiangsu Nanfang Medical Co's current Net Income (TTM) was -98.9. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jiangsu Nanfang Medical Co's current Cash Flow from Operations (TTM) was 82.7. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-98.882/1038.259
=-0.09523828

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-200.333/1259.908
=-0.15900605

Jiangsu Nanfang Medical Co's return on assets of this year was -0.09523828. Jiangsu Nanfang Medical Co's return on assets of last year was -0.15900605. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Jiangsu Nanfang Medical Co's current Net Income (TTM) was -98.9. Jiangsu Nanfang Medical Co's current Cash Flow from Operations (TTM) was 82.7. ==> 82.7 > -98.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=67/971.8608
=0.06893991

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=17.135/1186.098
=0.01444653

Jiangsu Nanfang Medical Co's gearing of this year was 0.06893991. Jiangsu Nanfang Medical Co's gearing of last year was 0.01444653. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=316.711/660.136
=0.47976629

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=392.444/733.674
=0.53490242

Jiangsu Nanfang Medical Co's current ratio of this year was 0.47976629. Jiangsu Nanfang Medical Co's current ratio of last year was 0.53490242. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Jiangsu Nanfang Medical Co's number of shares in issue this year was 282.795. Jiangsu Nanfang Medical Co's number of shares in issue last year was 293.257. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=22.855/584.68
=0.03908976

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-16.837/634.357
=-0.02654184

Jiangsu Nanfang Medical Co's gross margin of this year was 0.03908976. Jiangsu Nanfang Medical Co's gross margin of last year was -0.02654184. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=584.68/1038.259
=0.56313502

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=634.357/1259.908
=0.5034947

Jiangsu Nanfang Medical Co's asset turnover of this year was 0.56313502. Jiangsu Nanfang Medical Co's asset turnover of last year was 0.5034947. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+0+1+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jiangsu Nanfang Medical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Jiangsu Nanfang Medical Co (SHSE:603880) has a Piotroski F-Score of 6 as of Jul. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jiangsu Nanfang Medical Co and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Jiangsu Nanfang Medical Co's Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Jiangsu Nanfang Medical Co ranks #150 out of 801 companies in the Medical Devices & Instruments industry, placing it in the top 18.7%.
Is Jiangsu Nanfang Medical Co's Piotroski F-Score too high?
Jiangsu Nanfang Medical Co's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Jiangsu Nanfang Medical Co's value of 6 is 20% above this industry median. Based on the distribution chart, Jiangsu Nanfang Medical Co ranks #150 out of 801 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Nanfang Medical Co has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Nanfang Medical Co's Piotroski F-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Jiangsu Nanfang Medical Co ranks #150 out of 801 companies for Piotroski F-Score. This places Jiangsu Nanfang Medical Co in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Jiangsu Nanfang Medical Co's value of 6 is 20% above this benchmark. Historically, Jiangsu Nanfang Medical Co's own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Jiangsu Nanfang Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Nanfang Medical Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jiangsu Nanfang Medical Co and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Nanfang Medical Co's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Nanfang Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co (SHSE:603880) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.71, compared to a current price of ¥6.96 — trading 47.8% above its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Jiangsu Nanfang Medical Co's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Jiangsu Nanfang Medical Co (SHSE:603880), the current Piotroski F-Score is 6 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Nanfang Medical Co (SHSE:603880) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co stock appears to be overvalued. The current stock price of ¥6.96 is trading 47.8% above its estimated GF Value™ of ¥4.71. GuruFocus considers Jiangsu Nanfang Medical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603880:

  • Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
  • GF Value™: ¥4.71 vs. price of ¥6.96 (47.8% above fair value)
  • GF Score™: 50/100 with 3 warning signs
  • Industry Position: 20% above the Medical Devices & Instruments median (#150 of 801)

No single metric tells the full story. See the SHSE:603880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Nanfang Medical Co Business Description

Address Guo Xiang Road, Economic Development Zone, Jiangsu Province, Wujin, CHN, 213149
Jiangsu Nanfang Medical Co Ltd is a domestic adhesive dressing production enterprise that integrates research and development, production, and sales. It produces a band-aid in China. The company is focused on the development of self-owned brand products such as first-aid kits, sports protection products, and care products on the basis of the original series of Miaoshou medical dressings.
50GF Score

Get the complete analysis for SHSE:603880

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.96
Price
¥4.71
GF Value